



## **ASX ANNOUNCEMENT**

**January 17<sup>th</sup>, 2011**

---

### **Genetic Technologies executes Settlement Agreement with Sunrise Medical Laboratories**

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to report, in accordance with ASX Continuing Disclosure Rules, that it has settled a dispute with another US biotechnology company.

Sunrise Medical Laboratories (“Sunrise”) of Hicksville, New York, USA, which is associated with Sonic Healthcare Limited, has now entered into a Settlement Agreement with Genetic Technologies. Sunrise was one of the original parties to the patent infringement law suit filed by Genetic Technologies in the US District Court, Western District of Wisconsin earlier this year (refer ASX announcement dated February 16<sup>th</sup>, 2010).

Genetic Technologies can further report it is now also engaged in discussions with other parties pertaining to this law suit and further details will be released to the Market as additional settlement agreements are duly executed. Genetic Technologies is also engaged in negotiations with other parties, outside of this law suit, and details of relevant outcomes from these discussions will be similarly reported to the Market, at the appropriate time.

#### **About Genetic Technologies Limited**

Genetic Technologies was an early pioneer in recognising important new applications for “non-coding” DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its three-pronged business strategy includes: 1) the global commercialisation of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business with a focus on oncology and cancer management; and 3) the commercialisation of its various research and development projects aimed at generating further intellectual property of potentially global commercial significance. For more information, please visit [www.gtglabs.com](http://www.gtglabs.com).

---

#### **FOR FURTHER INFORMATION PLEASE CONTACT**

Dr. Paul D.R. MacLeman  
Chief Executive Officer

Genetic Technologies Limited  
Phone: +61 3 8412 7000